Reference is to Printer's Date 3/26/14--S.
Amend the bill, as and if amended, Section 44-53-110(27), SECTION 1, page 6, beginning on line 1, by striking the item in its entirety and inserting:
/ (27)(a) 'Marijuana' means:
(1)(i)
all species or variety of the marijuana plant and
all parts thereof whether growing or not;
(2)(ii) the
seeds of the marijuana plant;
(3)(iii) the
resin extracted from any part of the marijuana plant; or
(4)(iv) every
compound, manufacture, salt, derivative, mixture, or preparation
of the marijuana plant, marijuana seeds, or marijuana resin.
(b)
'Marijuana' does not mean:
(1)(i) the
mature stalks of the marijuana plant or fibers produced from
these stalks;
(2)(ii) oil or
cake made from the seeds of the marijuana plant, including
cannabidiol derived from the seeds of the marijuana
plant;
(3)(iii) any
other compound, manufacture, salt, derivatives, mixture, or
preparation of the mature stalks (except the resin extracted
therefrom), including cannabidiol derived from mature
stalks;
(4)(iv) the
sterilized seed of the marijuana plant which is incapable of
germination;
(v)
for persons participating in a clinical trial or
in an expanded access program related to administering
cannabidiol for the treatment of severe forms of epilepsy
pursuant to Article 18, Chapter 53, Title 44, a drug or
substance approved for the use of those participants by the
federal Food and Drug Administration; or
(vi)
for persons, or the persons' parents, legal
guardians, or other caretakers, who have received a written
certification from a physician licensed in this State that the
person has been diagnosed by a physician as having Lennox
Gastaut Syndrome, Dravet Syndrome, also known as 'severe
myoclonic epilepsy of infancy', or any other severe form of
epilepsy that is not adequately treated by traditional medical
therapies, the substance cannabidiol, a nonpsychoactive
cannabinoid, or any compound, manufacture, salt, derivative,
mixture, or preparation of any plant of the genus cannabis that
contains nine-tenths of one percent or less of
tetrahydrocannabinol and more than fifteen percent of
cannabidiol.
(c)
For purposes of this item, written certification
means a document dated and signed by a physician stating that
the patient has been diagnosed with Lennox Gastaut Syndrome,
Dravet Syndrome, also known as 'severe myoclonic epilepsy of
infancy', or any other severe form of epilepsy that is not
adequately treated by traditional medical therapies and the
physician's conclusion that the patient might benefit from the
medical use of cannabidiol.
(d)
A physician is not subject to detrimental
action, including arrest, prosecution, penalty, denial of a
right or privilege, civil penalty, or disciplinary action by a
professional licensing board for providing written certification
for the medical use of cannabidiol to a patient in accordance
with this section. /
Amend further, Article 18, Chapter 53, Title 44, SECTION 2, by inserting after line 23 / Julian's Law /
Amend further, Section 44-53-1810(1), SECTION 2, page 8, beginning on line 25, by striking the item in its entirety and inserting:
/ (1) 'Academic medical center' means a research hospital that operates a medical residency program for physicians and conducts research that involves human subjects, and other hospital research programs conducting research as a sub-recipient with the academic medical center as the prime awardee. /
Amend further, Section 44-53-1810(3), SECTION 2, page 8, beginning on line 38, by striking the item in its entirety and inserting:
/ (3) 'Cannabidiol' means a finished preparation containing, of its total cannabinoid content, at least 98 percent cannabidiol and not more than 0.90 percent tetrahydrocannabinol by volume that has been extracted from marijuana or synthesized in a laboratory. /
Renumber sections to conform.
Amend title to conform.